Margaret A. Fearon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Margaret A. Fearon has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
Vito Scalia
Canadian Blood Services, Ottawa, Ontario, Canada
4 shared publicationsMark Bigham
Medical Department, Canadian Blood Services, BC and Yukon, Vancouver, British Columbia, Canada
2 shared publicationsMary Huang
Canadian Blood Services; Ottawa Ontario Canada
2 shared publicationsMomar Ndao
Canadian Blood Services; Ottawa Ontario Canada
2 shared publications- Patricia Hewitt
Microbiology Services, NHS Blood and Transplant, London, UK
2 shared publications - Pierre Gallian
Unité des Virus Émergents (UVE: Aix-Marseille Univ-Corsica Univ-IRD 190-Inserm 1207-IRBA), Marseille, France
2 shared publications
Latest Publications
- 10 April 2019
- Published by Wiley in Vox Sanguinis
- Vol. 114 (4) , E1-E35
International Forum on Occult hepatitis B infection and transfusion safety
- 10 April 2019
- Published by Wiley in Vox Sanguinis
- Vol. 114 (4) , E1-E35
International Forum on Occult hepatitis B infection and transfusion safety
- 10 April 2017
- Published by Wiley in Transfusion
- Vol. 57 (6) , 1420-1425
Hepatitis E in Canadian blood donors
BACKGROUND: Hepatitis E virus (HEV) is a virus of emerging importance to transfusion medicine as studies on blood donors and other populations demonstrate that the prevalence of endemic cases is higher than previously recognized and the risk to vulnerable transfusion recipients is not insignificant.STUDY DESIGN AND METHODS: We carried out an HEV prevalence study on 13,993 Canadian blood donors with polymerase chain reaction (PCR) testing on all donors and antibody testing on a subset of 4102 donors. HEV antibody–positive and age‐ and sex‐matched antibody‐negative donors were invited to participate in a scripted telephone interview about risk factors.RESULTS: There were no PCR‐positive samples found (95% confidence interval [CI], 0%‐0.026%). The seroprevalence of HEV in our tested population was 5.9% (95% CI, 5.16%‐6.59%). HEV antibody positivity was associated with male sex and increasing age. In case‐control analysis history of living outside Canada (odds ratio [OR], 2.9; 95% CI, 1.56‐5.32) and contact with farm animals (OR, 1.5; 95% CI, 1.01‐2.28) were associated with HEV seropositivity.CONCLUSION: This is the largest data set to date on HEV infection in Canada. Results suggest low lifetime exposure to HEV and that infectious donations are rare.
- 10 April 2017
- Published by Wiley in Transfusion
- Vol. 57 (6) , 1420-1425
Hepatitis E in Canadian blood donors
BACKGROUND: Hepatitis E virus (HEV) is a virus of emerging importance to transfusion medicine as studies on blood donors and other populations demonstrate that the prevalence of endemic cases is higher than previously recognized and the risk to vulnerable transfusion recipients is not insignificant.STUDY DESIGN AND METHODS: We carried out an HEV prevalence study on 13,993 Canadian blood donors with polymerase chain reaction (PCR) testing on all donors and antibody testing on a subset of 4102 donors. HEV antibody–positive and age‐ and sex‐matched antibody‐negative donors were invited to participate in a scripted telephone interview about risk factors.RESULTS: There were no PCR‐positive samples found (95% confidence interval [CI], 0%‐0.026%). The seroprevalence of HEV in our tested population was 5.9% (95% CI, 5.16%‐6.59%). HEV antibody positivity was associated with male sex and increasing age. In case‐control analysis history of living outside Canada (odds ratio [OR], 2.9; 95% CI, 1.56‐5.32) and contact with farm animals (OR, 1.5; 95% CI, 1.01‐2.28) were associated with HEV seropositivity.CONCLUSION: This is the largest data set to date on HEV infection in Canada. Results suggest low lifetime exposure to HEV and that infectious donations are rare.
- 20 March 2017
- Published by Wiley in Vox Sanguinis
- Vol. 112 (4) , e1-e21
Vox Sanguinis International Forum on donor notification and counselling strategies for markers of transfusion‐transmissible infections
- 20 March 2017
- Published by Wiley in Vox Sanguinis
- Vol. 112 (4) , e1-e21
Vox Sanguinis International Forum on donor notification and counselling strategies for markers of transfusion‐transmissible infections
- 15 April 2016
- Published by Wiley in Transfusion
- Vol. 56 (4) , 994-995
Routine nucleic acid testing of blood donations fails to detect all human immunodeficiency virus-positive blood donors
- 15 April 2016
- Published by Wiley in Transfusion
- Vol. 56 (4) , 994-995
Routine nucleic acid testing of blood donations fails to detect all human immunodeficiency virus-positive blood donors
- 25 April 2013
- Published by Wiley in Transfusion
- Vol. 54 (3pt2) , 863-869
Evaluation of selective screening of donors for antibody toTrypanosoma cruzi: seroprevalence of donors who answer “no” to risk questions
Background Selective testing of donors for Trypanosoma cruzi infection relies on identification of at-risk donors with screening questions. Using risk modeling and a seroprevalence study, we evaluated the risk of questions failing to identify T. cruzi antibody–positive donors. Study Design and Methods The rate of donors with unreported risk was estimated by a telephone survey of 2677 donors who answered “no” to risk questions. The number of T. cruzi antibody–positive donors missed by risk questions was estimated from the product of this rate and the selective testing T. cruzi antibody–positive rate. The 95% confidence interval (CI) was estimated by Monte Carlo simulation. To test the model, 60,132 donors were tested for T. cruzi antibody (26% of donors in selected regions, Phase I). In Winnipeg, Manitoba, the highest-risk region, 26,915 donors were tested (92.5% of donors, Phase II). Results In the telephone survey, 21 (0.8%) donors reported risk factors that would have identified them for selective testing. Seven were born in Mexico or Central or South America, five had travel risk, and nine had mother or maternal grandmother risk. The 95% CI for predicted number of T. cruzi antibody–positive donors answering “no” to risk questions was 0.71 to 4.38. In Phase I, one Winnipeg donor confirmed positive but had answered risk questions correctly. No other positive donations were identified. Conclusion The estimated risk of T. cruzi–positive donors who answer “no” to risk questions is low and is confirmed by the seroprevalence among these donors.
- 25 April 2013
- Published by Wiley in Transfusion
- Vol. 54 (3pt2) , 863-869
Evaluation of selective screening of donors for antibody toTrypanosoma cruzi: seroprevalence of donors who answer “no” to risk questions
Background Selective testing of donors for Trypanosoma cruzi infection relies on identification of at-risk donors with screening questions. Using risk modeling and a seroprevalence study, we evaluated the risk of questions failing to identify T. cruzi antibody–positive donors. Study Design and Methods The rate of donors with unreported risk was estimated by a telephone survey of 2677 donors who answered “no” to risk questions. The number of T. cruzi antibody–positive donors missed by risk questions was estimated from the product of this rate and the selective testing T. cruzi antibody–positive rate. The 95% confidence interval (CI) was estimated by Monte Carlo simulation. To test the model, 60,132 donors were tested for T. cruzi antibody (26% of donors in selected regions, Phase I). In Winnipeg, Manitoba, the highest-risk region, 26,915 donors were tested (92.5% of donors, Phase II). Results In the telephone survey, 21 (0.8%) donors reported risk factors that would have identified them for selective testing. Seven were born in Mexico or Central or South America, five had travel risk, and nine had mother or maternal grandmother risk. The 95% CI for predicted number of T. cruzi antibody–positive donors answering “no” to risk questions was 0.71 to 4.38. In Phase I, one Winnipeg donor confirmed positive but had answered risk questions correctly. No other positive donations were identified. Conclusion The estimated risk of T. cruzi–positive donors who answer “no” to risk questions is low and is confirmed by the seroprevalence among these donors.
- Open Access
- 1 January 2013
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 24 (1) , 32-34
A Case of Vertical Transmission of Chagas Disease Contracted via Blood Transfusion in Canada
Chagas disease is caused by the protozoan parasite Trypanosoma cruzi and is endemic in many countries in Latin America, where infected bugs of the Triatominea subfamily carry the parasite in the gut and transmit it to humans through fecal contamination of a bite. However, vertical transmission and transmission through blood transfusion and organ transplantation is well documented. Increasing immigration from endemic countries to North America has prompted blood operators, including Canadian Blood Services and Hema Quebec, to initiate blood donor testing for Chagas antibody. In the present report, an unusual case of vertical transmission from a mother, most likely infected through blood transfusion, and detected as part of a concurrent seroprevalence study in blood donors is described.
- 1 January 2013
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 24 (1) , 32-34
Open AccessA Case of Vertical Transmission of Chagas Disease Contracted via Blood Transfusion in Canada
Chagas disease is caused by the protozoan parasite Trypanosoma cruzi and is endemic in many countries in Latin America, where infected bugs of the Triatominea subfamily carry the parasite in the gut and transmit it to humans through fecal contamination of a bite. However, vertical transmission and transmission through blood transfusion and organ transplantation is well documented. Increasing immigration from endemic countries to North America has prompted blood operators, including Canadian Blood Services and Hema Quebec, to initiate blood donor testing for Chagas antibody. In the present report, an unusual case of vertical transmission from a mother, most likely infected through blood transfusion, and detected as part of a concurrent seroprevalence study in blood donors is described.